Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Media Release Copenhagen, Denmark, 2 7 August, 202 1

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Genmab: Monoclonal Antibody Experts, Low Risk Business Model

Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2021 Results - Earnings Call Transcript

August 1 1 , 20 2 1 ; Copenhagen, Denmark; Interim Report for the First Half of 20 2 1

Genmab Announces Financial Results for the First Half of 2021

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021

Beam Therapeutics

Bolt Biotherapeutics

MacroGenics

Zai Lab Ltd.

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Alexion Pharma

ALXN vs. GMAB: Which Stock Is the Better Value Option?

ALXN or GMAB: Which Is the Better Value Stock Right Now?

Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Media Release Copenhagen, Denmark, June 1 , 2021 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer , Anthony Pagano and C hief D evelopment O fficer , Judith Klimovsky , will participate in a virtual fireside chat at the Goldman Sachs 4 2nd Annual Global Healthcare Conference 3: 50 PM EDT on June 9 , 202 1 (9: 50 PM CEST). A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-and-presentations#content

Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to Genmab A/S (NASDAQ: GMAB) and its partner Janssen Biotech Inc's Darzalex (daratumumab) subcutaneous for amyloidosis. The opinion is for daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone to treat adult patients with newly diagnosed systemic light-chain amyloidosis.

Genmab - Janssen's Darzalex Wins Positive Opinion In Europe For Two New Indications

Media Release Copenhagen, Denmark, May 21, 2021

Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call Transcript

Genmab Announces Financial Results for the First Quarter of 2021

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab

Seagen

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescript

Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

Novartis

Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license agreement with Genmab A/S (NASDAQ: GMAB).

Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis

Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis

Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

The company looks financially strong regardless of which angle it is analyzed from

Genmab: A Company With Downside Antibodies

Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript

Genmab announces initiation of share buy-back program

News for Genmab - ADR Stock (GMAB)